

Regeneron and Sanofi
DUPIXENT® (dupilumab)
Prix Galien USA 2025 “Best Biotechnology Product”
References for Submission

1. Evaluate Pharma syndicated data; based on consensus actuals & forecasts. April 2025.
2. Dupixent Prescribing Information. May 2025.
3. Gandhi, Namita A., et al. Targeting key proximal drivers of type 2 inflammation in disease. *Nature reviews drug discovery* 15.1 (2016): 35-50.
4. The emerging role of the Type 2 inflammatory cascade in atopic diseases. *AJMC*.
<https://www.ajmc.com/view/emerging-role-type-2-inflammatory-cascade-atopic-diseases>. Accessed May 30, 2025.
5. Paul WE. History of Interleukin 4. *Cytokine* (2015); 75(1): 3–7.
6. J.B. Bice et al. Biological Targeted Therapy in Allergic Asthma. *Ann Allergy Asthma Immunol* 112 (2014) 108e115.
7. Valenzuela DM, et al. High-throughput engineering of the mouse genome coupled with high-resolution expression analysis. *Nat Biotechnol* (2003); 21(6):652-9.
8. Macdonald LE, et al. Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes. *Proc Natl Acad Sci U S A* (2014); 111(14):5147-52.
9. Murphy AJ, et al. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. *Proc Natl Acad Sci U S A* (2014): 5153-8.
10. Stahl N, Yancopoulos GD. The alphas, betas, and kinases of cytokine receptor complexes. *Cell* (1993); 74(4):587-90.
11. Beck LA, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. *N Engl J Med* (2014); 371(2):130-9.
12. Wenzel S, et al. Dupilumab in Persistent Asthma with Elevated Eosinophil Levels. *N Engl J Med* (2013); 368:2455-2466.